Top Markets
#1 aelf aelf +16.47%
#2 Status Status +9.96%
#3 TDCCP TDCCP +9.11%
#4 DeXe DeXe +8.94%
#5 DAPPOS DAPPOS +8.01%
#6 HOME HOME +7.11%
#7 o1.exchange o1.exchange +6.32%
#8 Tutorial Tutorial +5.77%
#9 OpenGradient OpenGradient +5.52%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +4.94%
Coin of the day
aelf aelf
Settings
Language
ENGLISH
Currency
USD
Theme
LB Pharmaceuticals Inc Common Stock LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock

LBRX
Rank in Stocks #8002
This biopharmaceutical firm is currently in the clinical development stage,... This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Share Price
$48.45
Last synced: 2026-08-28
Market Cap
$1.39B
Change (1 day)
1.16%
Change (1 year)
-
Country
US
Trade LB Pharmaceuticals Inc Common Stock (LBRX)

Category

Healthcare
P/E ratio for LB Pharmaceuticals Inc Common Stock (LBRX)
P/E ratio as of 2026 TTM: 0
According to LB Pharmaceuticals Inc Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for LB Pharmaceuticals Inc Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.